knowledge -WSS

knowledge

author：comprehensive 2025-09-30 08:51:53 - browse：6

intarcia implant. -- health tech coverage from STAT — The matchstick-sized, implantable device from Intarcia Therapeutics releases a steady, continuous, and low-dose stream of a drug for diabetes. Stuart Isett/Fortune Brainstorm Health

An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.

Intarcia called for the panel meeting because of those two rejections, seeking outside input on the FDA’s decision. FDA then granted Intarcia’s request. The agency is not bound to advisory panel decisions, though it tends to follow their advice.

Intarcia started developing its lead therapy, a small, skinny bar implanted under the skin, for type 2 diabetes patients in 2016. The implant delivers a glucose-controlling medicine called exenatide, a member of the GLP-1 drugs that have taken the diabetes and obesity markets by storm. Intarcia’s implant continuously administers the drug over six months, with the goal of improving patient adherence compared to Eli Lilly and Novo Nordisk’s weekly GLP-1 shots.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Biohaven protein

WSS

Heat waves linked to early deliveries, preterm births in new study

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Trump surgeon general acknowledges mistakes during Covid

How to fix cancer clinical trials' diversity problem

The (many) problems with a new study criticizing cancer screening

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

focus

knowledge

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Snackable artificial intelligence, expert AI, and the pharma industry

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

AstraZeneca chief proposes a novel edit to the drug pricing bill

At least 13 dead in Texas as scorching temps continue

A rare thyroid diagnosis led to unexpected, all

Apple is now the first public company to be valued at $3 trillion

Listen: Biogen's potential pivot, & Illumina's next chapter

How one medical school became remarkably diverse

Insmed lung disease drug hits target in key Phase 3 trial

focus

What American doctors can learn from their Israeli counterparts

Stigma and the return of syphilis

Akili, maker of video game for ADHD, to be acquired for 34 million

NIH nominee Bertagnolli will get October confirmation hearing

First Opinion Podcast: What happens when kids become caregivers?

Trump surgeon general acknowledges mistakes during Covid

hotspot

explore

entertainment

explore